Trial Profile
A human abuse liability program for KP511
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Asalhydromorphone (Primary)
- Indications Acute pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 28 Jun 2017 According to a KemPharm media release, the company anticipates initiating this program in the second half of 2017. Data expected in the second half of 2017.
- 14 Sep 2016 New trial record